ライフサイエンスコーパス: immunogen

1 ZIKV vaccines using the envelope proteins as immunogens).

2 ion using a single recombinant hemagglutinin immunogen.

3 e utilize a mammalian non-self-antigen as an immunogen.

4 helical peptide epitope to create a superior immunogen.

5 sylated, soluble full-length protein vaccine immunogen.

6 can structures on a recombinant SARS-CoV-2 S immunogen.

7 s a reagent for serology, virology and as an immunogen.

8 al trial as a candidate bnAb vaccine priming immunogen.

9 e responses to this multivalent nanoparticle immunogen.

10 n to be a potential source of cancer vaccine immunogen.

11 se glycans than noncomplexed ch.SOSIP trimer immunogen.

12 P8-rTTHC) as a suitable FP-conjugate vaccine immunogen.

13 mimic the closed conformation in a designed immunogen.

14 us-neutralizing antibodies when delivered as immunogens.

15 may be enhanced in the development of future immunogens.

16 for the development of improved HIV envelope immunogens.

17 RV), was evaluated for the delivery of HIV-1 immunogens.

18 and testing of numerous scaffolded V2 region immunogens.

19 ied 5 protective Gag epitopes in the vaccine immunogens.

20 d of Env derived from both virus and soluble immunogens.

21 s could be elicited using carefully designed immunogens.

22 of antibody ID to viruses and other complex immunogens.

23 uccessfully selected as potential Cry1A(b)16 immunogens.

24 more efficiently with suitably optimized GP immunogens.

25 ochemical features of the germline-targeting immunogens.

26 e excellent templates for developing soluble immunogens.

27 ne response to competing antigens in complex immunogens.

28 acilitating the development of engineered V2 immunogens.

29 ng antibodies requires specifically designed immunogens.

30 on, structural studies, and use as potential immunogens.

31 and led directly to the development of novel immunogens.

32 cysteine-like protease, might also be potent immunogens.

33 d to design novel hemagglutinin (HA) vaccine immunogens.

34 us-neutralizing antibodies when delivered as immunogens.

35 uctural blueprints to design next-generation immunogens.

36 study of HIV spikes and their development as immunogens.

37 round the RBS will lead to more effective HA immunogens.

38 ing a potential route to engineer E2 vaccine immunogens.

39 bs alone and complexed with 426c-based gp120 immunogens.

40 hat can be elicited with currently available immunogens.

41 ture-based design of betacoronavirus vaccine immunogens.

42 onses compared to conventional alum-adsorbed immunogens.

43 be used to discriminate optimal virion-based immunogens.

44 n of broadly reactive antibodies by these HA immunogens.

45 B cells than those inoculated with parental immunogens.

46 t included in the initial wave of Warp Speed immunogens.

47 in designing the next generation of powerful immunogens.

48 g, Ag-specific memories of a wide variety of immunogens.

49 oves the immunogenicity of select Env trimer immunogens.

50 properties offer a template for H7N9 vaccine immunogens, a promising candidate therapeutic, and a too

51 gagement will help researchers to develop an immunogen able to elicit antibodies that block HIV-1 tra

52 e abilities of three such germline-targeting immunogens against the VRC01-class receptors to activate

53 Mechanistically, pSer-immunogen:alum complexes form nanoparticles that traffic

54 capsulating a stabilized HIV envelope trimer immunogen and adjuvant, supported on a dissolving polyme

55 nded Ab breadth elicited by a COBRA HA-based immunogen and advances efforts toward design and impleme

56 Breadth was elicited with a single trimer immunogen and did not require additional envelope divers

57 re there is genetic mismatch between vaccine immunogen and endogenous virus; this highlights the majo

58 ation for a recombinant trimer Spike mimetic immunogen and for a soluble version of human ACE2.

59 e necessary elements for RaxX function as an immunogen and host peptide hormone mimic.

60 oxide (alum) was found to be the most potent immunogen and induced high titer of neutralizing antibod

61 l integrity of the full-length spike protein immunogen and provides a basis for interpreting immune r

62 clinical vaccine program, we have identified immunogens and a vaccine regimen that induces a highly d

63 enting a step towards the rational design of immunogens and drugs inhibiting HCV entry.

64 immunized these bovines with different VEEV immunogens and evaluated the protective efficacy of puri

65 Here, we tested multiple immunogens and immunization strategies head-to-head to d

66 imitations of the current germline-targeting immunogens and of the animal models used to test them, a

67 igenic and immunogenic potential of E2-based immunogens and provide a pathway for the development of

68 elp researchers to develop effective vaccine immunogens and treatments.

69 tRNA) (a potent mitochondrial-derived innate immunogen) and a concomitant upregulation of innate immu

70 reactivity properties were activated by each immunogen, and these differences correlated with distinc

71 ly identified B. burgdorferi proteins, lipid immunogens, and live mutants lead the design of canonica

72 evelopers a "glycosylation target" for their immunogens, and they show how protein production variabl

73 all immune cells responding to a foster dam immunogen are the product of the foster pup's thymus.

74 New HIV-1 envelope immunogens are being engineered to selectively expose th

75 Effective HIV-1 immunogens are therefore likely to involve some degree o

76 ity to mount an immune response to exogenous immunogens, are able to block the development of autoimm

77 passive immunity to inform the selection of immunogens as candidates for active immunization and vic

78 unmet demand by investigating novel chimeric immunogens as carriers for recombinant peptide motif gra

79 A multimeric immunogen based on the founder MPER activated B cells be

80 This resulted in epitope-based immunogens based on a cyclic defensin protein, as well a

81 Immunogens based on consensus sequences might have utili

82 tudy, we rationally designed several vaccine immunogens based on the structure of a conserved epitope

83 heir development, suggesting that sequential immunogen-based vaccine regimens will likely need to inc

84 cient Env derivatives can be used as priming immunogens because they should engage and activate a mor

85 sidues enhances binding to alum and prolongs immunogen bioavailability.

86 We found that both types of immunogen boosts enhanced potentially protective antibod

87 In vitro, these immunogens bound more strongly to bnAb precursors once t

88 tructural modification of the HIV-1 envelope immunogen by cross-linking of gp140 with the CD4-mimetic

89 duction of antibodies facilitating uptake of immunogens by antigen-presenting cells.

90 ocked this epitope in BG505 SOSIPv4.1 trimer immunogens by knocking in an N-linked glycan at residue

91 his result shows that a properly constructed immunogen can be an effective vaccine in animals previou

92 Overall, we show that epitope-focused immunogens can boost subdominant neutralizing antibody r

93 These results demonstrate that HIV-1 protein immunogens can elicit durable memory T- and B-cell respo

94 mains to be proven if vaccination with these immunogens can elicit T cells with the ability to suppre

95 tial immunization with specifically designed immunogens can induce high levels of somatic mutation an

96 ver, the physical characteristics of peptide immunogens can limit their pharmacokinetic and immunolog

97 etition and indicate that germline-targeting immunogens can overcome these challenges with high-affin

98 aturation, but lacks full-length Env and Gag immunogens, can prevent intravaginal infection in a stri

99 ses and thus it constitutes a promising oral immunogen candidate in the fight against enteric disease

100 These locked dimers are strong immunogen candidates for a next-generation vaccine.

101 an be utilized to engineer HIV-1 Env vaccine immunogens capable of eliciting antibody responses with

102 Vaccine immunogens capable of re-eliciting these membrane proxim

103 veloped novel bivalent mosaic T-cell vaccine immunogens composed of conserved regions of the Gag and

104 measure the NII for different epitopes on an immunogen comprised of the receptor-binding domain from

105 altered angle of approach, we engineered an immunogen consisting of gp120 core in complex with the p

106 nea pigs of FP-directed responses induced by immunogens containing the most prevalent FP8 sequence (F

107 rally related to the important mycobacterial immunogen cord factor.

108 n proteins with selective glycan deletion as immunogens could focus Ab response toward CD4bs epitope.

109 rimed by eOD-GT8 60mer, a germline-targeting immunogen currently in clinical trials, recruited to ger

110 es against HIV in the next generation of HIV immunogens currently being developed.

111 DC localization in MBL-deficient mice or via immunogen deglycosylation significantly affected antibod

112 l surface engineering on the next generation immunogen, DEKnull-2, provides an immunogenicity breakth

113 3 responses and demonstrated that continuous immunogen delivery could enhance nAb responses.

114 timization studies revealed a correlation of immunogen density with antibody titers.

115 quiring a systematic approach to Env mimetic immunogen design and evaluation of elicited responses.

116 recognition of Env, which may inform vaccine immunogen design and immunotherapeutic development.

117 election of specific antibody nucleotides by immunogen design can be applied to B cell lineages targe

118 A concern in the trimer immunogen design field has been whether the latter off-t

119 , suggesting the importance of the region in immunogen design for maternal vaccines to prevent MTCT.I

120 on of HIV-1 Env were then employed to inform immunogen design in a proof-of-concept exploration of si

121 yet described, and are the current focus of immunogen design in HCV vaccine development; thus, makin

122 tly isolated bNAbs, the rational approach to immunogen design is to make a stable version of the Env

123 Taken together, these data can facilitate immunogen design to achieve antibody neutralization and

124 onstrates a rational strategy for sequential immunogen design to circumvent the difficult roadblocks

125 itical for understanding how to improve upon immunogen design to inform further testing in human clin

126 brane insertion for fusion, pave the way for immunogen design to protect against pathogenic hantaviru

127 nose-type glycans is an important feature in immunogen design, as glycans contribute to or influence

128 vaccine development include structure-based immunogen design, gene-based vaccine platforms and formu

129 topes of topological importance for rational immunogen design, including a T cell-based HIV vaccine.

130 To guide immunogen design, we seek a comprehensive understanding

131 can inform the biophysical mechanism and aid immunogen design.

132 even contradictory, hindering rational MPER immunogen design.

133 atures of human bNAbs, thereby guiding HIV-1 immunogen design.

134 antibodies provides insights that may guide immunogen design.

135 r understanding of its function and limiting immunogen design.

136 of these antibodies can provide insights for immunogen design.

137 aches based on germline-targeting and serial immunogen design.

138 for other env genes, thereby further guiding immunogen design.

139 es for passive immunotherapy and for guiding immunogen design.

140 ass bNAbs and guidelines for structure-based immunogen design.

141 This new information might be useful in immunogen design.

142 nisms of S recognition and conformations for immunogen design.

143 zing antibodies and the template for vaccine immunogen design.

144 Nonetheless, all trimeric and monomeric Env immunogens designed to date have failed to elicit such a

145 mice and wild-type macaques vaccinated with immunogens designed to select for improbable mutations.

146 aluable new opportunities for ontogeny-based immunogens designed to select for rare V2-bNAb precursor

147 ility of sequentially administered, modified immunogens (designed to bind progressively more mature b

148 he humoral responses elicited by these novel immunogen designs in nonhuman primates is critical for u

149 era from rabbits immunized with several CONE immunogens display Env binding activity.

150 uman primates, the full-valency nanoparticle immunogen displaying 20 DS-Cav1 trimers induced neutrali

151 er, with which we engineered epitope-focused immunogens displaying complex structural motifs.

152 cine regimens, and potentially adjuvants and immunogen dose, influence the elicitation of V2-specific

153 d discussion on the importance of validating immunogen doses and standardizing the general design (e.

154 In addition, the epitope-focused immunogen efficiently boosts antibodies targeting the pa

155 mpared with their wild-type derivatives, cvD immunogens elicited antibodies with a higher capacity to

156 Thus, our immunogens elicited antibody responses in macaques and k

157 in boost regimen with these new gp120 trimer immunogens elicited potent neutralizing antibody respons

158 ctions of antibodies elicited by novel HIV-1 immunogens engineered to improve exposure of specific ep

159 Both boost immunogens enhanced the breadth of HIV-1 gp120 and V1V2

160 The germline-targeting HIV immunogen eOD-GT8 60mer is currently in clinical trial a

161 Here, we display the clinical vaccine immunogen eOD-GT8, an engineered outer domain of the HIV

162 responses than those to other envelope-based immunogens, even in animal models.

163 us nAb lineages are induced by BG505 and B41 immunogens, even when both were administered together.

164 the present generation of native-like trimer immunogens, exemplified by the BG505 SOSIP.664 construct

165 DNA expressing an HIV V1V2 trimeric scaffold immunogen followed by booster immunizations with a combi

166 to generate tetramers for use as prime-boost immunogens, followed by selective enrichment of Ag-speci

167 able from wild type, proving its value as an immunogen for a future generation of vaccines against th

168 purified with self-histones and was a potent immunogen for BALB/c mice.

169 often include multiple variants for a given immunogen for better coverage of the extensive viral div

170 effective HIV-1 envelope glycoprotein (Env) immunogen for elicitation of broadly neutralizing antibo

171 noparticles (IO-NPs) to create a particulate immunogen for neutralizing antibody (NAb) induction.

172 Thus, RC1 may be a suitable priming immunogen for sequential vaccination strategies in the c

173 Env adds to the increasing pool of potential immunogens for a HIV-1 vaccine, particularly for clade C

174 platform for administration of glycopeptide immunogens for focusing immune responses to specific bnA

175 Thus, they are attractive immunogens for vaccine development.

176 and safe vector for the delivery of foreign immunogens for vaccine purposes.

177 The pSer-modified immunogens formulated in alum elicited greatly increased

178 h, we designed vaccines comprised of protein immunogens fused to an immunodominant CD4(+) T cell epit

179 plement-, mannose-binding lectin (MBL)-, and immunogen glycan-dependent manner.

180 ng of glycan holes, was obtained from trimer immunogen groups with the highest occupancy of the N241

181 s specific for 5 Gag epitopes in the vaccine immunogens had strong ability to suppress HIV-1 replicat

182 Immunogens have been designed that activate these B cell

183 cked guidance on how to assess whether their immunogens have optimal glycosylation.

184 G505-derived HIV envelope glycoprotein (Env) immunogens have revealed that the dominant autologous ne

185 These Env trimers when used as immunogens, have led to the first vaccine-induced neutra

186 Germline-targeting immunogens hold promise for initiating the induction of

187 may facilitate the design of V1V2-targeting immunogens.IMPORTANCE Many epitopes of the HIV envelope

188 NPs are particularly efficacious as priming immunogens, improve the quality of the Ab response over

189 We solved the X-ray structure of a cyclic immunogen in complex with the HCV1 antibody and confirme

190 hile including multiple variants for a given immunogen in prime-boost vaccination strategies is one a

191 s of the SOSIP design are being developed as immunogens in human immunodeficiency virus type 1 (HIV-1

192 The proteins were then evaluated as immunogens in mice to demonstrate the induction of funct

193 accine efficacy can be increased by arraying immunogens in multivalent form on virus-like nanoparticl

194 mited experience with recombinant trimers as immunogens in nonhuman primates, which are typically use

195 haracterized the new trimers, tested them as immunogens in rabbits, and found that the blocking glyca

196 When tested as immunogens in rabbits, the AMC009 trimers did not induce

197 When we tested these trimers as immunogens in rabbits, the induction of V3 non-NAbs was

198 cination strategy, which uses mismatched Gag immunogens in the TamoVac 01 phase IIa trial.

199 igated CTLs specific for Pol epitopes in the immunogens in treatment-naive Japanese patients infected

200 macaques with the CD4 binding site-targeting immunogen induced CD4 binding site serum neutralizing an

201 S-529-complexed V3 glycan-targeting ch.SOSIP immunogen induced in the majority of immunized animals h

202 S-529 complexed to CD4 bs-targeting ch.SOSIP immunogen induced stronger neutralization against tier 2

203 rimates, cocktails of three de novo-designed immunogens induced robust neutralizing responses against

204 Immunogens inducing antibodies against the stem of influ

205 urrounding surface on the germline-targeting immunogen influence its interaction with the available r

206 ormation and demonstrate that our engineered immunogen is able to elicit high neutralizing antibody t

207 However, the development of such immunogens is often complicated by inefficiencies in the

208 ign improvements that could eventually yield immunogens of practical value for solving the long-stand

209 icity of DS-SOSIP.4mut suggest utility as an immunogen or a serologic probe; moreover, the specific f

210 stabilized trimers may have utility as HIV-1 immunogens or in other antigen-specific contexts, such a

211 (-/-) YUMM1.1 tumor model that expresses the immunogen, ovalbumin (YOVAL1.1).

212 omology between the MVA- and DNA Gag-encoded immunogens (P = 0.04, r(2) = 0.47).

213 of SOSIP trimers make these NPs a promising immunogen platform.

214 Highly multimerized immunogens preferentially rapidly activated cognate B ce

215 t a computationally designed epitope-focused immunogen presenting a single RSV neutralization epitope

216 his program consisted of a cocktail of three immunogens presenting V2 from different viruses and clad

217 Mice vaccinated with our designed immunogens produced robust antibody responses to epitope

218 More importantly, these immunogens protected animals from lethal challenge with

219 Peptide immunogens provide an approach to focus antibody respons

220 high-affinity conditions using a multivalent immunogen, rare VRC01-class B cells successfully compete

221 thin polyclonal repertoires, we developed an immunogen, RC1, that facilitates the recognition of the

222 key aspects of HIV-1 Env immunogenicity and immunogen re-design, based on experimental data generate

223 Furthermore, the immunogens refocused preexisting antibody responses towa

224 ors), have been engineered to evaluate novel immunogens/regimens for effectiveness in driving bnAb re

225 d B41, the prospect of designing prime-boost immunogens remains difficult.

226 d B41, the prospect of designing prime-boost immunogens remains difficult.IMPORTANCE A glycan hole is

227 odies-and thus of interest for the design of immunogens-remains unknown.

228 Native-like HIV-1 Env immunogens representing distinct clades have been propos

229 thymus, the maternal or foster pup origin of immunogen-responding CD8(+) cells in foster pup spleens

230 ed in the first few weeks after weaning, all immunogen-responding CD8(+) T cells were pup derived by

231 At this age, 82% of immunogen-responding cells in the pup spleen were produc

232 s for a given clinical end point will inform immunogen selection and guide preclinical and clinical e

233 ational cytotoxic T-lymphocyte-based vaccine immunogen selection for both subtype-specific and univer

234 ticulate presentation strategies for the RBD immunogen should be considered for inducing strongly neu

235 We show that immunogens should exhibit differences in affinity across

236 Specifically, the engineered immunogens should have their cross-reactive epitopes mas

237 Ideally, Env immunogens should present broadly neutralizing antibody

238 that a proportion was positive for maternal immunogen-specific MHC class II tetramers.

239 Immunogen-specific VRC01-like B cells were isolated at d

240 Current approaches to immunogen stabilization involve iterative application of

241 Following immunization of mice, this immunogen strategy generated four Tspan15 antibodies.

242 pathogens with complex proteins as candidate immunogens such as HIV, influenza, and coronaviruses.

243 nverted the purified 3F7.A10 mAb into a weak immunogen, suggesting that the mAb had formed immunogeni

244 ltiple trimers as sequential or simultaneous immunogens, targeting the germline precursors of bNAbs,

245 , we address the challenge of identifying an immunogen that can elicit potent, broadly protective, an

246 FLSC is a CD4-gp120 fusion immunogen that exposes cryptic gp120 epitopes to the imm

247 (NHP) study using a V3 glycopeptide minimal immunogen that was structurally optimized to be recogniz

248 In this study, we designed a panel of novel immunogens that 1) preferentially expose the CD4bs by se

249 Advances in the design of immunogens that antigenically mimic the HIV envelope gly

250 We hypothesized that vaccination with immunogens that bind with moderate to high affinity to b

251 We designed two HIV-1 envelope immunogens that bound precursor B cells of either a CD4

252 ovel adjuvants and inclusion of trimeric Env immunogens that could eventually elicit a higher level o

253 e production of highly ordered, monodisperse immunogens that display DS-Cav1 at controllable density.

254 strategies are needed to design recombinant immunogens that display these critical immune targets.

255 These results may aid the design of immunogens that elicit antibodies to the trimer apex.

256 The design of immunogens that elicit broadly reactive neutralizing ant

257 sign of self-assembling protein nanoparticle immunogens that elicit potent and protective antibody re

258 technology was effectively used to design HA immunogens that elicited antibodies that neutralized H5N

259 f HIV-1 vaccine development is the design of immunogens that induce broadly neutralizing antibodies (

260 great strides in the development of envelope immunogens that mimic the virus particle, but less is kn

261 We identified immunogens that minimized non-neutralizing V3 responses

262 We then developed HIV envelope trimer-based immunogens that primed responses from rare bnAb-precurso

263 trategies to develop arenaviral glycoprotein immunogens that resemble GPC as presented on the mature

264 show important differences between the noted immunogens that should be borne in mind when considering

265 ond successfully designing several novel HCV immunogens, this study demonstrates the principle that n

266 tly designed conserved mosaic T-cell vaccine immunogens (tHIVconsvX) composed of 6 Gag and Pol region

267 No immunogen to date has reliably elicited broadly neutrali

268 ncrease the diversity of gp120 motifs in the immunogen to elicit a broader antibody response and enha

269 ress this knowledge gap, here we designed an immunogen to generate the first monoclonal antibodies ta

270 This epitope represents a novel immunogen to potentially develop diagnostic antibodies o

271 e rationale for the use of PilA as a vaccine immunogen to prevent NTHI-induced diseases of the respir

272 Thus inclusion of additional gp120 immunogens to a pox-prime/protein boost regimen can augm

273 study indicates that the design of effective immunogens to activate B cell receptors leading to prote

274 are reviewed: firstly, the use of sequential immunogens to activate B cells to express bNAbs; secondl

275 Engineering immunogens to avoid this MBC diversity may facilitate fl

276 gn of germline targeting and boosting trimer immunogens to create an antigenic conformation optimal f

277 w insights for the design of optimized Gn/Gc immunogens to elicit protective immune responses.

278 h HIV and influenza virus, and the design of immunogens to elicit them is a goal of vaccine research

279 for the intranasal delivery of nucleic acid immunogens to improve protective efficacy.

280 e I), we performed structure-based design of immunogens to induce antibody responses to this epitope.

281 ng HCV envelope glycoprotein E2, we designed immunogens to modulate the structure and dynamics of E2

282 ilized amyloid protofibrils could be used as immunogens to prepare conformation-specific antibodies a

283 line precursors and are therefore unsuitable immunogens to prime supersite-bnAb responses.

284 In this model, enteral administration of immunogen trinitrobenzene sulfonate (TNBS) in 10-d-old m

285 fficiently to soluble forms of the optimized immunogen, unless it is highly multimerized.

286 Point mutations in the immunogen V2 HS to match the V2 HS in the challenge viru

287 The immunogen was created in an ADAM10-knockout mouse cell l

288 otein with enhanced enzymatic activity as an immunogen, we generated fully human monoclonal antibodie

289 By using novel engineered DBP immunogens, we validate that the prime targets of protec

290 Novel immunogens were designed to focus the antibody response

291 Similarly, we found that HA stem immunogens were poorly immunogenic compared with the ful

292 The Env immunogens were selected from envs emerging during the e

293 a stable prefusion conformation of the spike immunogen with slight differences in the S1 subunit comp

294 clic defensin protein, as well as a bivalent immunogen with two copies of the epitope on the E2 surfa

295 Here, using HIV immunogens with defined valencies ranging from 1 to 60,

296 The ability to design immunogens with high mimicry to viral proteins also make

297 monstrate that site-specific modification of immunogens with short peptides composed of repeating pho

298 s specific for 6 Pol epitopes present in the immunogens with strong abilities to suppress HIV-1 in vi

299 resulted in multiple homogeneous cross-clade immunogens with the potential to advance HIV vaccine dev

300 odies (bNAbs) by HIV-1 envelope glycoprotein immunogens would be a major advance toward an effective